

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, Washington, D.C. 20231
on December 11, 2001

By: Debbie Ellis
Printed Name

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Matthew R. Kaser

Title: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES

Serial No.: 09/919,039

Filing Date: July 30, 2001

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual

of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.


If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: December 11, 2004 David S. Strube Reg. No. 43,168
for Lynn E. Murry, Ph.D.
Reg. No. 42,918
Direct Dial Telephone: (650) 845-4159

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office				Atty Docket No.		Serial No.	
				PA-0035 US		09/919,039	
				LIST OF REFERENCES CITED BY APPLICANTS (Use several sheets if necessary)			
				Applicant(s)			
				Kaser			
				Filing Date		Group	
				July 30, 2001		To Be Assigned	
U.S. Patent Documents							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Foreign Patent Documents							
						Translation	
		Document	Date	Country	Class	Subclass	Yes No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1	Mickelson et al., "Differential Expression and Release of CD54 Induced by Cytokines", <u>Hepatol.</u> , 22: 866-875 (1995).					
	2	Nagendra et al., "CD18 integrin and CD54-dependent neutrophil adhesion to cytokine-stimulated human hepatocytes", <u>Am. J. Physiol.</u> , 272: G408-G416 (1997).					
	3	Hasmall, S.C. and R.A. Roberts, "The Perturbation of Apoptosis and Mitosis by Drugs and Xenobiotics", <u>Pharmacol. Ther.</u> , 82: 63-70 (1999).					
	4	Gelman, L. et al., "An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer", <u>Cell. Mol. Life Sci.</u> , 55: 932-943 (1999).					
	5	Kawashima, H. et al., "Protein Expression, Characterization, and Regulation of CYP4F4 and CYP4F5 Cloned from Rat Brain", <u>Arch. Biochem. Biophys.</u> , 347: 148-154 (1997).					
	6	Zhou, S. and K. B. Wallace, "The Effect of Peroxisome Proliferators on Mitochondrial Bioenergetics", <u>Toxicol. Sci.</u> , 48: 82-89 (1999).					
Examiner			Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.							